Renchi Yang, MD

Head of Thrombosis and Hemostasis Center
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Tianjin, Hebei, China (People's Republic)

Dr. Renchi Yang is Professor and Head of Thrombosis and Hemostasis Center at Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC). He is Steer Committee member of East Asia Hemophilia Forum and the Association for Hemophilia and Allied Disorders-Asia-Pacific (AHAD-AP). He is Director of the National Hemophilia Registry Center, Chairman of the Hemophilia Treatment Center Collaborative Network of China, Chairman of National Hemophilia Cooperative Group. He is currently the translated edition (Chinese) editor of Haemophilia, the official journal of the World Federation of Hemophilia (WFH).

Presentation(s):

• OC 05.2 - Metabolomics profile and machine learning prediction of treatment responses in immune thrombocytopenia: a prospective cohort study

  Saturday, June 22, 2024
  13:15 – 13:30 ICT

• LB 01.1 - Safety, tolerability, and efficacy of mezagitamab (TAK-079) in chronic or persistent primary immune thrombocytopenia: Interim results from a phase 2, randomized, double-blind, placebo-controlled study

  Sunday, June 23, 2024
  09:30 – 09:45 ICT

• OC 13.2 - Proteomics Landscape and Machine Learning Prediction of Long-term Response to Splenectomy in Primary Immune Thrombocytopenia

  Sunday, June 23, 2024
  09:45 – 10:00 ICT

• PB0242 - A phase I tiral evaluating safety and pharmacokinetics in human and an ex vivo pharmacodynamics study in hemophilia patients of KN057, the first anti–TFPI monoclonal antibody in China

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0212 - Evaluation of Omfiloctocog alfa (SCT800) Efficacy in Real-World Treatment of Severe Hemophilia A in China: Insights from the SURPASS Study

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0271 - Health Literacy of People with Haemophilia in China – Results of a Cross-sectional, Community-Based Survey

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0265 - Reduced doses of emicizumab achieve good efficacy: results from a national-wide multicenter real-world study in China

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• OC 21.5 - An Open-label,Dose-Escalation,Multicenter Phase I Study to Evaluate the Safety,Immunogenicity,and Pharmacokinetics/pharmacodynamics（PK/PD）of Single Dose SS109 in Hemophilia A/B patients with Inhibitor

  Sunday, June 23, 2024
  15:45 – 16:00 ICT

• SOA 08.4 - Acquired bleeding disorders

  Monday, June 24, 2024
  08:00 – 09:15 ICT

• PB0562 - Combined Factor V and Factor VIII deficiency in China: Phenotype and current status of management

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• PB0571 - Congenital factor Ⅴ deficiency in China

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• PB0691 - Kabuki syndrome complicated by severe immune thrombocytopenia and autoimmune thyroiditis: identification of a novel pathogenic mutation

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• PB0676 - Spleen Microbiota Dysbiosis Play a Role in Response to Splenectomy in Patients with Primary Immune Thrombocytopenia: a Prospective Cohort Study

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• OC 40.1 - A Novel Extended half-life factor VIII Fc fusion protein FRSW107 for severe hemophilia A: A multicentre, open-label, single-arm, phase 3 study and its open-label extension

  Monday, June 24, 2024
  14:45 – 15:00 ICT

• PB1313 - Platelet Multi-omics Analysis Confirms Hyperglycemia as a Risk Factor for Thrombosis in JAK2V617F-positive Essential Thrombocythemia

  Tuesday, June 25, 2024
  13:45 – 14:45 ICT